Citi raised the firm’s price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an “upside 90-day catalyst watch” on Olema. The firm says Roche’s (RHHBY) positive Phase 3 lidERA trial data shows the “practice changing” potential of selective estrogen receptor degraders for adjuvant treatment of breast cancer. The data bode well for Olema, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology files automatic mixed securities shelf
- Olema Oncology price target raised to $48 from $45 at Oppenheimer
- Olema Oncology price target raised to $38 from $26 at Goldman Sachs
- Promising Potential of Olema Pharmaceuticals’ Palazestrant in Transforming ER+/HER2- Breast Cancer Treatment
- Positive Outlook for Olema’s OPERA-02 Trial Based on Roche’s Promising Giredestrant Data